2008
DOI: 10.1134/s0006297908120043
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: Mitochondria-targeted cationic plastoquinone derivative SkQ1 (10-(6'-plastoquinonyl) decyltriphenylphosphonium) has been investigated as a potential tool for treating a number of ROS-related ocular diseases. In OXYS rats suffering from a ROS-induced progeria, very small amounts of SkQ1 (50 nmol/kg per day) added to food were found to prevent development of age-induced cataract and retinopathies of the eye, lipid peroxidation and protein carbonylation in skeletal muscles, as well as a decrease in bone mineraliz… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
85
0
2

Year Published

2009
2009
2018
2018

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 130 publications
(93 citation statements)
references
References 31 publications
6
85
0
2
Order By: Relevance
“…Furthermore, we only tested one dose. In this respect, other studies have clearly shown the dose used by us to be optimal in inbred and outbred rodents in longevity studies [16,48]. However, it is possible that the full blockade of HF-induced ROS production was too rigid, dissipating putative beneficial effects of ROS, such as stimulation of endogenous antioxidant capacity or mitochondrial biogenesis, which themselves might in turn affect insulin sensitivity.…”
Section: Discussionmentioning
confidence: 93%
See 1 more Smart Citation
“…Furthermore, we only tested one dose. In this respect, other studies have clearly shown the dose used by us to be optimal in inbred and outbred rodents in longevity studies [16,48]. However, it is possible that the full blockade of HF-induced ROS production was too rigid, dissipating putative beneficial effects of ROS, such as stimulation of endogenous antioxidant capacity or mitochondrial biogenesis, which themselves might in turn affect insulin sensitivity.…”
Section: Discussionmentioning
confidence: 93%
“…A third group of mice received the HF plus the SkQ antioxidant (HF+SkQ). Based on previous studies, an SkQ dose of 250 nmol/kg body weight [16] was supplemented throughout the study via the drinking water [17]. Water bottles for all mice were refreshed three times per week, and body weight and food intake were measured weekly.…”
Section: Methodsmentioning
confidence: 99%
“…This effect was accompanied by retardation of the development of many age-related diseases and traits (2,14,(18)(19)(20)(21). When studying the molecular mechanism of the effects of SkQs, we usually employed C 12 TPP as the control compound.…”
mentioning
confidence: 99%
“…9 Moreover, SkQ1 increases the aB-crystallin level and decreases the Ab level in the retina (manuscript in preparation) as well as in the brain. 40 These findings are consistent with the present study and support the view that aB-crystallin is involved in degeneration of the retina.…”
Section: Discussionmentioning
confidence: 99%
“…SkQ1 at nanomolar concentrations is capable of not only preventing the development of AMD-like retinopathy in OXYS rats but also reversing the existing pathological alterations in the retina. [9][10][11][12] It was also shown that SkQ1 has a therapeutic potential against other agerelated diseases 9,[13][14][15][16][17] and increases the lifespan. 18,19 It is believed that the development of retinopathy in OXYS rats, just like AMD in humans, is associated with progressive mitochondrial dysfunction 20,21 and with accumulation of b-amyloid.…”
Section: Introductionmentioning
confidence: 99%